Professor Heather Payne is a Consultant Clinical Oncologist, specialising in urological and prostate cancer at University College London Hospitals NHS Trust and she also sees patients privately, including at The Harley Street Clinic and The Prostate Centre.

Professor Payne trained at St Mary’s Hospital and after qualifying, spent time in general medicine in London and Haiti.

On her returned to London, she trained as a Clinical Oncologist, and also developed an interest in urological oncology.

In addition to her clinical work, she is also actively involved in research, and she has pioneered a program of high-dose rate brachytherapy for prostate cancer. Current research interests include hormone therapy, sensitisation of hormones and radiotherapy, predictive indices for bowel toxicity with radiotherapy, proton beam therapy for prostate cancer, chemotherapy and assisting men with decision making and prostate cancer.

Professor Payne is principal investigator in a number of international and national studies and has been published in peer-reviewed journals. She is Chair of the British Uro-oncology Group and Oncology Lead for the National Prostate Cancer Audit. She also serves on the Prostate Cancer Advisory Group for the UK.

• External Beam Radiotherapy
• Intensity Modulated Radiotherapy/Rapid Arc
• Low Does Brachytherapy
• Hormone Treatment

• Prostate Cancer
• Novel Hormone Therapy
• External beam radiotherapy
• Chemotherapy
• Brachytherapy
• 
  

Dr Mulholland is a medical Oncologist who exclusively treats brain cancer at University College Hospital, the National Hospital for Neurology and Neurosurgery (part of UCLH) and Mount Vernon Cancer Centre.He is also an honorary senior lecturer at UCL and a training programme director. 

His doctoral research was in genomic profiling in brain cancer at Cancer Research UK - this has led to his focus on developing biomarkers and targets for therapy in brain cancer, including the clinical trial portfolio of novel agents in brain cancer which he now runs at UCLH and nationally. 

He is a clinical lead in a European Consortium called Datrix, a multidisciplinary European collaboration to advance next-generation targeted hyperthermic cancer treatment for glioblastoma.

• Cancer prevention and screening 
• Chemotherapy 

• Brain cancer 
• Neuro-endocrine tumours 
• Central nervous system cancer 
• Novel agents 

Dr Sarah Harris has been a Consultant Clinical Oncologist working at Guy’s and St Thomas’ NHS Trust for over 20 years. She now only sees patients privately at a range of private centres across London as well as by remote video consultation . Her areas of interests include breast cancer, prostate cancer and urological cancer, and she treats these conditions using radiotherapy and chemotherapy in central London and the south east of England.

She has extensive clinical experience in the management of breast cancer using radiotherapy and drug treatments. She has a specialist interest in technical radiotherapy due to its maximal benefits and reduced side effects. In particular she uses heart sparing radiotherapy techniques for left-sided breast radiotherapy. Furthermore, she regularly uses stereotactic radiotherapy for the treatment of localised recurrent cancers using the latest radiotherapy technologies, cyberknife and SABR. For the treatment of prostate cancer, she can perform external radiotherapy using modern IMRT and IGRT.

Along with her wealth of experience, she completed specialist training in proton beam radiotherapy at the University Of Pennsylvania in 2020. Dr Harris also holds many professional memberships, including the Royal College of Physicians and the Royal College of Radiologists.

In her leisure time , she is a keen golfer aspiring to a single figure handicap.

• Radiotherapy
• Chemotherapy
• CyberKnife therapy
• Stereotactic Ablative Radiotherapy (SABR)
• Proton beam radiotherapy

• Breast Cancer
• Prostate Cancer
• Urological Cancers

Dr. John Conibear completed his initial medical training at the University Hospital of Wales in 2001 and completed his post-graduate general medical training in The Barts and The London Training rotation in 2006. Before gaining his substantive post as a consultant clinical oncologist in St. Bartholomew’s Hospital in 2014, he completed a 2-year fellowship with the NCRI Radiotherapy Trials Quality Assurance Group in Mount Vernon Hospital. During his fellowship, he conducted research into techniques to improve clinician target outlining during radiotherapy planning and was subsequently awarded an MD(Res) from UCL in 2018.

Dr. Conibear is currently deputy medical director and deputy director of Barts Cancer Centre. Dr Conibear specialises in all the non-surgical treatments for both lung and breast cancers. He has expertise in chemotherapy, biological therapy, immunotherapy, radiotherapy and state of the art radiotherapy techniques including deep inspiration breath-hold (DIBH) for early breast cancer, Intensity Modulated Radiotherapy (IMRT), Image-Guided Radiotherapy (IGRT), 4D-CT and both Cyberknife and Gamma Knife (stereotactic radiotherapy). He is also currently the lead for chemotherapy and clinical director for thoracic oncology in St. Bartholomew’s Hospital in addition to his private practice.

• Chemotherapy
• Deep Inspiration Breath Hold
• Gamma Knife
• Image-guided radiotherapy (IGRT)
• Immunotherapy
• Intensity modulated radiotherapy (IMRT)
• Radiotherapy

• Breast cancer
• Lung cancer

Dr Amen Sibtain is a Consultant Clinical Oncologist specialising in the management of Gastrointestinal, Hepatobiliary and Head and Neck cancers with chemotherapy and radiotherapy. He is also highly experienced in chemo-radiotherapy, state of the art radiotherapy techniques, including VMAT, stereotactic radiotherapy and radiosurgery, and intraoperative radiotherapy.

Dr Sibtain is presently the Clinical Director of GI oncology and Radiotherapy at St Bartholomew’s Hospital, an examiner in oncology for the Royal College of Radiologists, a member of the medical advisory panel for both Macmillan and CRUK, oncology advisor for BBC Drama and the Clinical Lead in Head and Neck Cancer at Barts. Dr Sibtain was previously President of the Oncology Section of the Royal Society of Medicine, Programme Director for Clinical Oncology Specialist Training Committee for the London Deanery and Chairman of the Head and Neck Tumour Board for North East London. He also previously worked at the Royal Marsden, Mount Vernon and The Middlesex Hospitals, before he took up his post at Barts. He was awarded an MD degree for his research in tumour hypoxia by the University of London.

As well as his clinical work he remains actively involved in research. He has been published in a number of peer-reviewed journals and edited the books Towards the Prevention of Cancer (2007) and Physics for Clinical Oncologists (2012).

Diseases, Medical Tests and Treatments

• Chemotherapy
• Cyberknife Therapy
• Intensity Modulated Radiotherapy 
• Radio Surgery
• Radiotherapy
• Rapid Arc
• Stereotactic Radiotherapy 
• Volumetric Arc Radiotherapy 
• Anal Cancer
• Bilary Cancer
• Bowel Cancer  
• Colon Cancer
• Gastro-Intestinal Cancers
• Head & Neck Cancers
• Liver Cancer
• Oesophageal Cancer
• Pancreatic Cancer
• Rectal Cancer
• Stomach Cancer

It is important that HCA is transparent about our relationship with those doctors who provide us with clinical guidance on delivering the best possible care to patients and operating our hospitals safely and efficiently. We set out here some of the ways in which we work together and the amount we pay this doctor for such services.

Professor Paul Ellis is a Consultant Medical Oncologist based in London, UK. He has a specialist interest in research into novel therapies in breast cancer management was heavily involved in chairing the UK Dept. of Health Advisory committee on the introduction of Herceptin into UK clinical practise, co-authoring the national guidelines of its use.

After attaining his Medical Degree from Otago University, New Zealand he then moved to London to complete his fellowship in Medical Oncology and postgraduate research degree at the Royal Marsden Hospital. It was here he submitted his MD thesis on the biological predictors of response to primary chemotherapy. 

Professor Paul Ellis continues to take an active leadership role within the UK and European Clinical Trials community. He was the principal investigator and co-chair in the trial management group for the UK National Adjuvant Chemotherapy (TACT) Trial and has been heavily involved on the Steering Committees of numerous other clinical trials of novel anti-cancer therapies including recently being Co-PI on the MARIANNE and KAMILLA trials. 

Dr Mary McCormack is a Consultant Clinical Oncologist, specialising in gynaecological andf breast cancers. She qualified in medicine from Guy's and St Thomas' Hospital. Before medical school, she undertook research in radiation biology and was awarded a PhD in 1989. Dr McCormack has worked in leading London cancer centres and in 2000, she was awarded the FRCR in clinical oncology. She was appointed a consultant at University College London Hospital in 2002.

Dr McCormack treats all subtypes of gynaecological cancer, including ovary, womb, uterus, cervix, vulva, vagina and also treats breast cancer. Treatments include chemotherapy, targeted/ biological therapy,radiotherapy and brachytherapy. She has a particular interest in cervical cancer treatment and targeted agents in breast, ovarian and endometrial cancer. Dr McCormack is a major contributor to national and international clinical trials and is the chief investigator on a nuber of studies. She is the current chair of the international Cervical Cancer Research Network (CCRN)and an exective member of the Gynaecologic Cancer Intergroup (GCIG)and a member of the International Gynaecologic Cancer Society's education committee.She is also a member of the ASCO International Affairs Committee.

It is important that HCA is transparent about our relationship with those doctors who provide us with clinical guidance on delivering the best possible care to patients and operating our hospitals safely and efficiently. We set out here some of the ways in which we work together and the amount we pay this doctor for such services.

• Radiotherapy
• Chemotherapy
• Brachytherapy

• Cervical Cancer
• Breast Cancer
• Gynaecological Cancers
• uterine cancer
• vaginal and vulval cancer
• ovary cancer
• chemotherapy 
• biological therapy
• radiotherapy

Dr Daniel Krell is a Consultant Oncologist, specialising in gastro-oesophageal, colorectal, pancreatic, liver and bile duct cancers and neuroendocrine tumours. He is experienced in using chemotherapy, targeted therapy and immunotherapy. Dr Krell also manages patients with cancer of unknown primary and is the clinical lead for this. He works as a member of the multidisciplinary team for gastro-oesophageal and hepatobiliary cancer at the Royal Free Trust. He is also the clinical lead for Neuroendocrine tumour oncology at The Royal Free Hospital. 

He undertook oncology training at University College and the Royal Free Hospitals in London. In addition to his primary medical degree, he also gained a Bachelor’s degree in immunology and microbiology, in addition to a DPhil in Clinical Medicine at the University of Oxford’s Wellcome Trust Centre for Human Genetics and was funded by Cancer Research UK and HCA. His research involved the design of models to investigate the role that genetic mutations in genes controlling cellular metabolism play in the development of cancer. This may help identify new therapeutic targets in this area. Dr Krell continues to be involved in clinical research and trials aimed at identifying new cancer therapies, focused on gastrointestinal, hepatobiliary and neuroendocrine tumours. He has published a number of peer-reviewed papaers and presented at national and international conferences.

• Chemotherapy
• Immunotherapy
• Biological Therapy
• Genetic Testing

• Liver Cancer
• Biliary Cancer
• Bowel Cancer
• Colorectal Cancer
• Oesophageal Cancer
• Pancreatic Cancer

Dr Constantine Alifrangis is a Consultant Medical Oncologist in London. He specialises in the treatment of urological cancers including prostate, bladder, testicular and penile cancer.

He graduated from Guys’ Kings and St Thomas’ Medical school and was awarded the University Gold Medal for medicine. Following this, he completed his postgraduate medical training in oncology at Imperial College London. He undertook research into advanced prostate cancer at Hammersmith Hospital, and was awarded a Wellcome Trust fellowship to research the link between cancer genetics and the efficacy of novel therapies. He was awarded a PhD by the University of Cambridge in 2014 for this work. He was also awarded the Sylvia Lawler prize by the Oncology section of the Royal Society of Medicine.

In 2016, he was appointed Consultant Medical Oncologist at University College London Hospital and St Bartholomew’s. He is the Lead Oncologist for Testicular Cancer, treating patients with advanced prostate cancer and is part of a specialist team looking after patients with penile cancer.

He is actively involved in research into the genetic basis of cancer and drug resistance, including personalised approaches to cancer treatment. He is also the Lead Investigator for number of clinical studies looking at rarer and understudied cancers. He has presented his research at a number of international conferences and published research in various cancer journals including the Lancet, Journal of Clinical Oncology, and Clinical Cancer Research.

• Chemotherapy 

• Bladder Cancer
• Genito-urinary Cancer
• Penile Cancer
• Prostate Cancer
• Testicular Cancer

Martin graduated from the University of Newcastle upon Tyne and gained general medical experience in New Zealand, Australia and the United Kingdom, becoming a member of the Royal College of Physicians (UK) in 2000. Since then he has been working in cancer care, training in Medical Oncology at the Oxford Radcliffe and Royal Marsden NHS Trusts. During this time, he achieved a PhD at the Institute for Cancer Research, London, and was awarded the EORTC-PAMM Young Investigator Award in 2004. He completed his specialist training in Medical Oncology in 2008 and was appointed as a UCL Clinical Senior Lecturer and UCH Consultant in Medical Oncology in 2009. Since then he has been running a research-based practice and has been principal/chief investigator for more than 20 early and late phase clinical trials.

Martin is involved in the management of patients with both lung and head and neck cancers. He is interested in drug development and in using the increasing understanding of cancer biology to design studies that distinguish patient populations most likely to gain benefit from new drugs and new drug combinations. He has a particular interest in cancer biology that leads to the development of both lung and head and neck cancers.

• Chemotherapy

• Lung and head and neck cancers
• Drug development 
• Cancer biology